Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

The influence of age and gender on venous symptomatology. An epidemiological survey in Belgium and Luxembourg.

Vuylsteke ME, Colman R, Thomis S, Guillaume G, Degrande E, Staelens I.

Phlebology. 2016 Jun;31(5):325-33. doi: 10.1177/0268355515589224.

PMID:
26036248
2.

In antibody-positive first-degree relatives of patients with type 1 diabetes, HLA-A*24 and HLA-B*18, but not HLA-B*39, are predictors of impending diabetes with distinct HLA-DQ interactions.

Mbunwe E, Van der Auwera BJ, Weets I, Van Crombrugge P, Crenier L, Coeckelberghs M, Seret N, Decochez K, Vandemeulebroucke E, Gillard P, Keymeulen B, van Schravendijk C, Wenzlau JM, Hutton JC, Pipeleers DG, Gorus FK; Belgian Diabetes Registry..

Diabetologia. 2013 Sep;56(9):1964-70. doi: 10.1007/s00125-013-2951-8.

3.

HLA-A*24 is an independent predictor of 5-year progression to diabetes in autoantibody-positive first-degree relatives of type 1 diabetic patients.

Mbunwe E, Van der Auwera BJ, Vermeulen I, Demeester S, Van Dalem A, Balti EV, Van Aken S, Derdelinckx L, Dorchy H, De Schepper J, van Schravendijk C, Wenzlau JM, Hutton JC, Pipeleers D, Weets I, Gorus FK; Belgian Diabetes Registry..

Diabetes. 2013 Apr;62(4):1345-50. doi: 10.2337/db12-0747.

4.

Vorapaxar in the secondary prevention of atherothrombotic events.

Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, Fish MP, Fox KA, Lipka LJ, Liu X, Nicolau JC, Ophuis AJ, Paolasso E, Scirica BM, Spinar J, Theroux P, Wiviott SD, Strony J, Murphy SA; TRA 2P–TIMI 50 Steering Committee and Investigators..

N Engl J Med. 2012 Apr 12;366(15):1404-13. doi: 10.1056/NEJMoa1200933.

5.

Vildagliptin: a new oral treatment for type 2 diabetes mellitus.

Mathieu C, Degrande E.

Vasc Health Risk Manag. 2008;4(6):1349-60. Review.

Supplemental Content

Loading ...
Support Center